Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Q4 2024 Management View CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo, and EYLEA HD. He emphasized the acceleration in EYLEA ...

Reports Q4 revenue $3.79B, consensus $3.75B. “Regeneron’s (REGN) financial and commercial strength allows for continued investment in our ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up ...

However, beyond its impressive scientific achievements, investors should also note that the company has been led by the same CEO, Leonard Schleifer, since its founding in 1988. This leadership ...

Cox's net worth is $4.4 billion. #335 on the Forbes 400 List, Leonard Schleifer got his bachelor's degree from Cornell University before obtaining his M.D. and PhD from the University of Virginia.

Regeneron's CEO, Leonard Schleifer, once criticized arbitrary drug price increases by pharmaceutical companies. But in July, the company's eczema drug price increased by 3%. Regeneron said Sanofi ...

Eylea HD is poised to become the new standard-of-care for patients with wet age-related macular degeneration and diabetic eye diseases,” CEO Leonard Schleifer said on a call with investors early ...

The CEO and co-founder of biotech firm, Regeneron, Leonard Schleifer earn and annual salary of $452 million, as per reports. Reed Hastings, the co-founder and executive chairman of streaming giant ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $12.07, up 2% year-over-year, beating the ...

The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.